Key result
Targeted vascular imaging should be integrated with clinical-biological modifiers to reclassify patients with low 10-year risk scores who have subclinical atherosclerosis.
Answers are grounded in this paper and cite their sources.
This letter to the editor proposes a hybrid approach combining clinical risk scores, biological modifiers, and targeted vascular imaging to identify and reclassify young or middle-aged patients who have demonstrable subclinical atherosclerosis despite a low calculated 10-year risk.
Cardiovascular risk scores are central tools for primary prevention, but they should not be interpreted as diagnostic proof of the absence of atherosclerosis. In young or middle-aged adults, chronological age and the 10-year time horizon may yield low-risk estimates despite significant arterial disease. This discordance becomes clinically relevant when vascular ultrasound, coronary artery calcium scoring, or coronary computed tomography angiography identify an atherosclerotic burden not anticipated by the probabilistic model. We propose integrating estimated risk, clinical-biological modifiers, and targeted vascular imaging to reclassify discordant patients and adjust preventive intensity according to actually demonstrated disease.
No takes yet. Share an insight, caveat, or question.
Kohan et al. (2026) conducted a letter in Atherosclerosis and cardiovascular risk stratification in primary prevention. Targeted vascular imaging (vascular ultrasound, coronary artery calcium score, or coronary CT angiography) integrated with cardiovascular risk scores vs. Cardiovascular risk prediction scores alone (e.g., PREVENT, SCORE2) was evaluated. Targeted vascular imaging should be integrated with clinical-biological modifiers to reclassify patients with low 10-year risk scores who have subclinical atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: